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Five percent of all cancers in postmenopausal women are attributable to being 
overweight and the incidence rises to 51% in women with endometrial cancer 
(EC). EC patients that are obese tend to have a poorer outcome, shorter 
survival rates and more co-morbidities than their non-obese counterparts. 
However, the role of excess adipose tissue in increasing cancer risk is not well 
understood. More specifically, the exact role of intracellular signalling factors 
within adipose tissue, in the development of endometrial cancer, is still unclear. 
This project aimed to partially address this lack of understanding by carrying 
out a systematic review / meta-analysis of primary studies related to the role 
of circulating adipokines and inflammatory molecules in EC. Cochrane Central 
Register of Controlled Trials (CENTRAL), Cinahl, Web of Science, Medline and 
Embase databases were searched using key words: endometrial cancer, 
obesity, adiponectin, leptin, interleukin-6 (IL-6), tumour necrosis factor alpha 
(TNFα), insulin-like growth factor I (IGF-I), and insulin-like growth factor II 
(IGF-II).  
Obese, overweight and normal weight women with EC (n=25 including one 
patient with endometrial hyperplasia) were recruited into a small clinical study 
and blood samples taken for analysis of the above-mentioned inflammatory 
markers and adipokines. 
Results from the meta-analysis suggest that participants with circulating 
adiponectin levels in the highest tertile had 0.51 times decreased EC risk 
compared to women with levels in the lowest tertile (summary of odds ratio 
(SOR): 0.51, 95% confidence interval (CI): 0.38-0.069, p<0.00001). Women 
with circulating leptin concentrations in the highest tertile had 2.19 times 
increased EC risk compared to the women with concentrations in the lowest 
tertile (SOR: 2.19, 95% CI: 1.45-3.30, p<0.0002). Pooled results 
demonstrated no significant differences in TNFα and IL-6 circulating levels 
between participants with the highest levels compared to the lowest levels. 
In this small clinical study, higher concentrations of leptin, TNFα, IL-6, IGF-I 
and IGF-II were observed in obese patients with EC compared to overweight 
 
IV 
and normal weight patients with EC. Adipocytokines may act synergistically to 
increase the risk and development of EC in women with different BMI.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Endometrial cancer 
The number of women diagnosed with endometrial cancer continues to rise 
each year. In 2010, there were 8,475 new cases and, in 2014, this rose to 
9,324 in the United Kingdom (UK): 65% increase in the incidence of 
endometrial cancer has been reported since 1980 (Cancer Research UK, 2018). 
The American Cancer Society (2018) estimated 61,880 new cases of 
endometrial cancer will be diagnosed in 2019, in the United States of America. 
The risk of developing endometrial cancer has been shown to be increased in 
overweight (a body mass index (BMI) of 25-29.9 kg/m2) and obese (a BMI of 
30 kg/m2 and above) women (Calle and Kaaks, 2004). Renehan and colleagues 
(2008) demonstrated, in their meta-analysis and systematic review of 
prospective studies a 1.6-fold increase in endometrial cancer risk with each 
extra 5 kg/m2 BMI. Endometrial cancer is most common in post-menopausal 
women; the average age women reach the menopause in the UK, is 51 years 
of age. The incident of endometrial cancer is highest in the 75-79-year age 
group, increasing steeply from around ages 45-49 years (Cancer Research UK, 
2018). Women usually present with abnormal vaginal bleeding or discharge. 
However, the bleeding can be heavy and irregular in pre-menopausal women. 
The diagnosis of endometrial cancer is usually confirmed on an endometrial 
biopsy with approximately 80% of women requiring surgery in the form of a 
hysterectomy bilateral salpingo-oophorectomy and dependent on the stage 
and grade of the tumour may require removal of pelvic and para-aortic lymph 
nodes as treatment. A further 21% will require radiotherapy and 16% 
chemotherapy (Cancer Research UK, 2018). Figures 1.1 and 1.2 are schematic 
diagrams of the female reproductive system and of the location of the 
endometrium, respectively. The International Federation of Gynecology and 
Obstetrics (FIGO) staging is the method used to stage and, assess the extent 









Figure 1.2 The development of endometrial cancer from the endometrium. Adapted 




Table 1.1 TNM (8th Edition) FIGO staging for endometrial cancer (2009) 
 Description 
Primary Tumour (T) 
TNM FIGO  
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
T1 I Tumour is confined to the uterus 
T1a 1A Tumour involves the endometrium and invades less than 
50% of the myometrium 
T1b 1B Tumour involves the endometrium and invades more than 
50% of the myometrium  
T2 II Tumour extends to the cervical stroma but is still confined 
to the uterus. 
T3 III Regional spread of the tumour beyond the uterus 
T3a IIIA Tumour has spread to the serosa of the uterus and/or to 
the fallopian tubes and/or ovaries 
T3b IIIB Tumour extends to the vagina and or parametrium 
T4 IVA Tumour invades bladder or bowel mucosa 
  Positive pelvic lymph nodes 
Regional Lymph Nodes (N) 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1,N2       IIIC Metastases to the pelvic and or para-aortic lymph nodes 
N1 IIIC1 Positive pelvic lymph nodes 
N2 IIIC2 Para-aortic lymph nodes involved with or without positive 
pelvic lymph nodes 
Distant Metastasis (M) 
M0  No distant metastasis 
M1 IVB Distant metastasis 





1.1.1 Histopathology of endometrial cancer 
There are two distinct types of endometrial cancer: Type 1 and Type 2; based 
on their distinct clinical/pathological and molecular identities (Bohkman, 1983) 
(Table 1.2).  
Table 1.2 Characteristics of Type 1 and Type 2 endometrial carcinomas 
Characteristics Type1 Type 2 
Unopposed oestrogen Present Absent 
Growth Slow growing Rapid progression 
Precursor Atypical hyperplasia Endometrial 
intraepithelial 
carcinoma 
Histology Endometrioid Serous, Clear cell 
Grade Low High 
Molecular genetic 
changes 






Source: Chu et al., 2008. 
Type 1 endometrial cancers are known as endometrioid type because of their 
similarity to normal endometrial glands. They are usually preceded by 
endometrial hyperplasia and are oestrogen related because of unbound 
oestrogen diffusing into the uterine cavity and stimulating the endometrium. 
They account for approximately 80% of all endometrial cancers and are 
diagnosed in both pre and post-menopausal women. 
Type 2 endometrial cancers are of a different histological type to Type 1 and 
usually are of the serous or clear cell type. Carcinosarcomas and 
undifferentiated tumours are also classified as Type 2 endometrial cancers. 
Type 2 endometrial cancers account for approximately 20% of endometrial 
cancers and are often diagnosed in post-menopausal women. They are high 
grade in nature and biologically more aggressive than Type 1. They can be 
preceded by endometrial intraepithelial carcinoma (Ambrose et al. 1995). They 




relapses occur in women with Type 2 endometrial cancers (Santin et al., 2005). 
Unlike Type 1 endometrial cancers, they are not associated with oestrogen 
stimulation as the endometrium is usually atrophic in women with Type 2 
endometrial cancers. The women can also be of normal weight because Type 
2 endometrial cancers are non-oestrogen dependent. It has been postulated 
that the development of Type 2 endometrial cancers is more likely to be related 
to mutations in oncogenic signalling pathways. Abnormalities in the tumour 
suppressor gene, p53, and the p53 protein in endometrial cancers, have been 
reported in several studies (Lax et al., 2000, Yamazawa et al., 2007, Horree 
et al., 2008). An increase in the over-expression of the p53 protein from normal 
endometrium to hyperplasia through to endometrial carcinoma has been 
demonstrated, suggesting a possible role in disease progression in endometrial 
carcinoma (Horree et al., 2008). 
Approximately 90% of endometrial cancers are sporadic and 10% hereditary 
(Bansal et al., 2009). Hereditary non-polyposis colorectal cancer (HNPCC), also 
known as lynch syndrome, is an inherited autosomal dominant syndrome due 
to defective mismatch repair (MMR) genes MLH1 (MutL homolog1), MSH2 
(MutL homolog 2) and MSH6 (MutL homolog 6). The MMR genes are 
responsible for repairing errors during DNA replication. Mutations in these 
genes will generate microsatellite instability (MSI). MSI have been well 
documented in endometrial cancers and are more common in Type 1 than Type 
2 endometrial cancers (Mackay et al., 2010). After colorectal cancers, 
endometrial cancer is the second most common cancer to develop in patients 
with HNPCC, with approximately 30-60% of women developing endometrial 
cancer. Endometrial cancer occurs 10 years earlier in women with HNPCC, than 
the general population, with peak incidence between the ages of 40-60 years. 
Up to 3% of women with endometrial cancer will have mutations in the MMR 
genes (Ellis and Ghaem-Maghami, 2010). 
The drive to develop strategies to reduce the risk of endometrial cancers and 
treatment options, have led to the identification of genomic alterations in 
endometrioid and serous endometrial cancers. Genomic classification of 
endometrial cancers has characterised them in to 4 molecular subgroups: pole 
ultramutated, microsatellite instability hypermutated, copy number low, copy 




has demonstrated that 25% of high grade endometrioid tumours have a 
molecular phenotype similar to serous endometrial carcinomas. These tumours 
have increased mutations in the p53 gene and also increased somatic copy 
alterations. This discovery has implications with regards to the treatment 
options available for these tumours. Chemotherapy for these high grade 
endometrioid tumours with a similar phenotype to serous endometrial 
carcinomas may be more appropriate than radiotherapy. 
 
1.2 Endometrial cancer and obesity 
The number of people classified as being overweight and obese has 
dramatically increased over the last few years in the UK. Obesity, which is 
defined as a BMI of greater than 30 kg/m2 and characterised by an excessive 
accumulation of fat in adipose tissue, is thought to be a factor in the 
development of several cancers including breast, renal, oesophageal, colon and 
endometrial (Basen-Enquist and Chang, 2011).  
The association between endometrial cancer and obesity is well documented 
at epidemiological level (Calle et al., 2003, Courneya et al., 2005). Five percent 
of all cancers in post-menopausal women are attributable to being overweight 
(BMI ≥25 kg/m2). For women with endometrial cancer, this rises to 51% 
(World Cancer Research Fund 2009, 2013). Women of normal weight have a 
3% lifetime risk of endometrial cancer compared to a 9-10% lifetime risk in 
obese women (Modesitt et al., 2012). This risk is also present in pre-
menopausal women. Moreover, patients who are obese tend to have a poorer 
outcome and more co-morbidities (e.g. hypertension, respiratory disease and 
type 2 diabetes) than their non-obese counterparts: mortality rates have been 
reported to be significantly higher with increasing BMI (Secord et al., 2016). 
In addition to the poorer outcome, Type 1 endometrial cancers tend to be more 
common in obese women. This is possibly due to the theory that the aetiology 
of Type 1 endometrial cancer is linked to oestrogen. Obese women will produce 
more oestrogen due to the conversion of androstenedione to oestrone by the 
enzyme aromatase in the adipose tissue (Felix et al., 2010).  
Several mechanisms have been put forward to explain the molecular link 




to better define such mechanisms, due to the complexity of the changes 
occurring to adipose tissue in an obese state.  
 
1.3 Adipose tissue 
There are three types of adipose tissue: brown adipose tissue (BAT), beige 
adipose tissue and white adipose tissue (WAT) and, each type differs in their 
location and species. BAT has an important function in thermoregulation in 
newborn infants and hibernating mammals. The amount of BAT decreases as 
a person ages (Virtanen et al., 2009). The BAT colour is derived from 
containing a higher number of iron containing mitochondria than WAT. Beige 
adipose tissue is also involved in thermoregulation and like BAT, the amount 
and function of beige adipose tissue decreases with age (Zoico et al., 2019). 
WAT contains trigylcerides and is the main site for energy storage (Saley et 
al., 2012). WAT can be further classified into visceral adipose tissue and 
subcutaneous adipose tissue. As a result of increased WAT, in an obese 
individual, the function of the adipose tissue can deteriorate resulting in a state 
of chronic inflammation. The abnormal inflammatory environment occurs as a 
result of at least 3 mechanisms: an increased production of inflammatory 
factors, increased tissue inflammation and adipose tissue remodelling 
(Ghigliotti et al., 2014). 
In this inflammatory state, adipocytes and macrophages secrete several 
molecules, adipokines and inflammatory cytokines, which may promote 
tumour development and angiogenesis and stimulate adhesions and migration 
of cells (Nieman et al., 2013). 
WAT (Figure 1.3) is an active endocrine gland which produces and secrete 
several hormones such as adiponectin, leptin, tumour necrosis factor alpha 





Figure 1.3 Adipose tissue and its secretion of different factors (Cordido et al., 2014) 
Adiponectin is involved in the control of glucose metabolism and fatty acid 
oxidation. Its plasma levels are generally lower in obese individuals (Kishida et 
al., 2014) and hypoadiponectinemia has been associated with diabetes and 
cancer. Moreover, losing weight through healthy eating, exercise or surgery 
increases adiponectin levels (Christiansen et al., 2010). Even though the 
mechanisms underlying the inverse relationship between body weight and 
adiponectin levels are still unclear, adiponectin has been shown to decrease 
blood glucose and insulin concentrations, and has anti-inflammatory and 
antiangiogenic properties (Dallal et al., 2013).  
Leptin is also predominantly produced by adipocytes and has an insulin 
sensitising effect contributing to insulin resistance. In the obese state, leptin 
levels are raised which in turn promote inflammation by stimulating the 
production of IL-6, TNFα as well as IL-1 and IL-12 (Carbone et al., 2012; 
Strong et al., 2015). Several studies have demonstrated an inverse 
relationship between adiponectin and leptin in endometrial cancer (Ashizawa 
et al., 2010; Ma et al., 2013; Wang et al., 2014). Higher adiponectin levels 
appear to have a protective effect in endometrial cancer (Gong et al., 2015, 
Tong et al., 2015). This contrasts with leptin which has been reported to be an 
independent risk factor for endometrial cancer (Wang et al. 2014). Another 




concentrations of leptin in obese post-menopausal women to determine 
whether it differed from concentrations in patients with a normal endometrium. 
They found, in their case control study of 86 obese post-menopausal women 
(40 with endometrial cancer/hyperplasia and 46 with normal endometrium), 
that the mean serum concentration of leptin in endometrial cancer/hyperplasia 
to be 16737.1 pg/ml as opposed to 9048.7 pg/ml in patients without 
endometrial pathology (p<0.0001). Serum leptin levels in women with 
endometrial hyperplasia with atypia was 1524 pg/ml and in women with 
endometrial cancer, it was 17,879 pg/ml compared to 9048.7 pg/ml in women 
with a normal endometrium. They concluded that leptin appears to participate 
in proliferative processes of the endometrium.  
The levels of TNFα, a pro-inflammatory cytokine produced by adipocytes, are 
raised in the obese state. Originally, described as a cytokine with anti-tumour 
properties, it was later found to have the opposite effect; promoting the 
development of cancer (Trayhurn and Wood, 2004). It has been shown to be 
involved in all stages of cancer development including progression and 
metastasis (Trayhurn et al., 2008). TNFα is a regulator of necrosis factor (NF)-
κB, which subsequently controls a complex of proteins involved in cell growth 
and proliferation (Aggarwal, 2004). Choi and colleagues (2009) demonstrated 
the role of TNFα in activating signalling pathways which are essential for 
migration of endometrial cancer cells. 
Another adipocyte inflammatory marker, IL-6, is increased in endometrial 
cancer and is associated with a poor prognosis (Bellone et al., 2005; Slater et 
al., 2006). It stimulates the release of acute phase proteins such as C-reactive 
protein (CRP) and is involved in the retention and proliferation of CD3+ and B 
lymphocytes respectively (Himbert et al., 2017). IL-6 has been shown to 
stimulate aromatase in the adipose tissue (Zhao et al., 1995). This can increase 
oestrogen production resulting in further stimulation of the endometrium and 
increase the risk of Type 1 endometrial cancers. Zemlyak and colleagues 
(2012) undertook a prospective study examining the expression of 
inflammatory cytokines in adipose tissue from patients with endometrial 
cancer. They assessed the gene expression of TNFα, IL-6, IκB (an inhibitor of 
NF-κB), CD68 (glycoprotein expressed on macrophages) and leptin in samples 




benign conditions. Omental tissue was harvested from the patients. The total 
number of patients was 56: 24 patients with endometrial cancer and 32 
controls. The gene expression of IκB TNFα, and IL-6 increased as BMI increased 
in the control group. There was no correlation of IκB TNFα, IL-6 or CD-68 gene 
expression levels with cancer status of the patients. Leptin had a weak 
protective effect against endometrial cancer. They concluded that obesity was 
associated with increased expression of certain inflammatory cytokines in the 
adipose tissue. However, increased levels of these inflammatory markers in 
adipose tissue of the omentum are not associated with the presence of 
endometrial cancer.  
Insulin and IGF levels are also increased in obesity (Wang et al., 2016). Insulin 
production from the pancreas is raised in individuals with insulin resistance. 
IGF-I is produced predominantly by the liver and plays a key role in normal 
growth and development. IGF-I and IGF-II are involved in mediating steroid 
hormone actions in the endometrium through autocrine and paracrine 
mechanisms. Both IGF-I and IGF-II are associated with endometrial 
differentiation. Insulin and IGF increased expression have been linked to 
endometrial cancer (Pavelic et al., 2007). The authors examined the expression 
of IGF-II and its receptors in 59 endometrial cancers, 10 hyperplasia and 7 
normal tissues. They found that levels of IGF-I and IGF-II receptors were much 
higher in the neoplastic tissue of Stage III and IV endometrial cancers 
compared to Stage I and II cancers and hyperplastic or normal endometrium. 
This correlated with a decreased apoptosis rate and IGF2R expression. They 
concluded that IGF-I, IGF-II and their receptors are involved in the progression 
of endometrial adenocarcinomas. 
Oestrogen has been implicated in the link between obesity and endometrial 
cancer (Vicennat et al., 2015). The synthesis and levels of circulating oestrogen 
change throughout the female reproductive years. In pre-menopausal women, 
the ovaries are the main source of oestrogen. This changes once a woman 
reaches the menopause; the ovaries are no longer the main source of 
oestrogen but, it is secreted from other sites such as the adrenal glands and 
adipose tissue. Adipose tissue is the main source of oestrogen in obese post-
menopausal women (Cleary and Grossmann, 2009). Obesity increases 




adipose tissue and the skin results in increased levels of oestrogen synthesis. 
Aromatisation is performed by the enzyme aromatase, which is found 
abundantly in adipose tissue. Aromatase converts androstenedione to 
oestrone. Increased circulating oestrogen levels have a stimulatory effect on 
the endometrium which can induce neoplastic transformation (Navaratnarajah 
et al., 2008). Obesity is also associated with the decreased production of the 
sex hormone binding globulin (SHBG) which results in the increase 
bioavailability of oestrogen. Obese pre-menopausal women tend to have more 
frequent anovulation leading to progestogen deficiency which increases 
unopposed oestrogen exposure (Pilay et al., 2006). Additional studies have 
also looked at the link between the amount of adiposity, levels of circulating 
adipokines and increased risk of endometrial cancer. In particular, the study 
by Mihu and colleagues, (2013) assessed the relationship between abdominal 
adiposity through adipocyte secretion products and the risk in developing 
endometrial cancer. The authors sought to identify a correlation between 
abdominal obesity, plasma adipokine levels (leptin and adiponectin) and 
endometrial cancer. This case-controlled analysis assessed two groups of 
patients; Group 1: 44 patients diagnosed with endometrial cancer and Group 
2: 44 patients without gynaecological pathology or inflammatory disorders. 
Group 1 had an average BMI of 32.49±4.66 kg/m2 and Group 2 average BMI 
of 24.55±4.0 kg/m2. Abdominal fat was assessed by dual X-ray absorptiometry 
and plasma adiponectin and leptin levels were measured using ELISA. A 
significantly higher value for abdominal fat and leptin was found in Group 1 
(p<0.0001), whilst the plasma adiponectin level was significantly lower in 
Group 1 (p<0.00001) compared to the control group (Group 2) (p<0.00001). 
Abdominal fat had a negative linear correlation with plasma adiponectin levels 
and a positive linear correlation with plasma leptin levels. They concluded that 
measurement of adiponectin and leptin levels associated with the 
determination of abdominal adipose tissue can be a useful predictor factor for 
endometrial cancer. 
1.4 Literature review of secondary research 
The literature currently available is quite fragmented and a systematic search 
of the literature was performed to capture secondary research investigating 




development and progression of endometrial cancer. A systematic literature 
search was, therefore, conducted within MEDLINE and Embase for articles that 
met the inclusion criteria by using the following key words: endometrial cancer, 
obesity, adipose tissue, adipocytes, adipokines, adiponectin, leptin, growth 
factors. The outcome of this search identified 4 meta-analysis of the published 
literature which are summarised below.  
Lin and colleagues (2015) performed a meta-analysis to assess the association 
between serum levels of adiponectin and the risk of endometrial cancer. 
Studies were identified by searching PubMed and the Web of Knowledge in 
January 2015 and had to include the following parameters: 1. case-control or 
cohort studies; 2. adiponectin levels as exposure of interest; 3. endometrial 
cancer as end-point result; 4. sufficient data generated to calculate relative 
risk (RR) or odds ratio (OR) with 95% Confidence Interval (CI) and 5. provision 
of each category of adiponectin levels for dose-response analysis. A random-
effect meta-analysis was carried out to assess the dose-response relationship 
between serum adiponectin levels and endometrial carcinoma using the 
methods suggested by Greenland and Longnecker (1992) and Orsini and 
Bellocco (2006). Twelve studies which included 5 prospective studies and 7 
case-control studies involving 1916 endometrial carcinoma cases were 
included in this meta-analysis. The results demonstrated the risk of 
endometrial carcinoma was found to be decreasing by 3% for every 1 µg/ml 
increase in adiponectin levels. The authors concluded that higher serum 
adiponectin levels may have a protective effect against endometrial carcinoma, 
especially in post-menopausal women. 
A similar meta-analysis by Zeng and colleagues (2015) also assessed the 
association between serum adiponectin concentrations and the risk of 
endometrial cancer. PubMed, Embase, the Chinese Biomedical Literature 
Database and the Science Citation Index were searched. Eight case-control 
studies, which included 1257 endometrial cancer patients and 1398 controls 
and four nested case-control studies including 659 endometrial cancer patients 
and 1398 controls were included. They reported serum adiponectin levels were 
inversely correlated with the risk of endometrial cancer development after 
pooling the case-control studies (OR=0.50, 95% CI: 0.39-0.60; p<0.001). The 




between serum adiponectin level and endometrial cancer, although a 
correlation may exist in the subgroup of post-menopausal women (OR=0.81, 
95% CI: 0.65-1.00; p=0.060) and particularly in post-menopausal women 
without current hormone replacement therapy (OR=0.62, 95% CI: 0.44-0.86; 
p=0.004). The meta-analyses on the association between adiponectin and 
endometrial cancer risk appear to support a positive effect; higher levels of 
adiponectin suggest a lower risk for endometrial cancer. 
Wang and colleagues (2014) performed a meta-analysis to assess whether 
high leptin levels were an independent risk factor for endometrial cancer. 
PubMed, Web of Science and Embase databases were searched for suitable 
studies published up to June 2014. The pooled RR with 95% CI was used to 
assess the association between leptin levels and risk of endometrial cancer 
(RR=2.55, 95% CI: 1.91-3.41). The results found that a high leptin level was 
associated with an increased risk of endometrial cancer (RR=1.59, 95% CI: 
1.27-1.98, p<0.001) and was an independent risk factor for endometrial 
cancer.  
In addition, Gong and colleagues (2015) also conducted a meta-analysis into 
the associations between circulating adiponectin and leptin, the adiponectin-
leptin ratio and endometrial cancer risk. PubMed and ISI Web of Science 
databases were searched for relevant studies. Eight case-control studies and 5 
nested case-control studies involving a total of 1,963 endometrial cancer cases 
and 3,503 controls were included in the meta-analysis. The results from the 
meta-analysis supported the above findings of Wang et al. (2014); increased 
circulating levels of leptin concentrations were associated with an increased 
risk of endometrial cancer. They also concurred with the Zeng et al. (2015) 
study: increased circulating adiponectin and adiponectin/leptin ratio were 
associated with a decreased risk of endometrial cancer.  
 
1.5 Research aims 
Despite the current studies available in the literature on adiponectin and leptin, 
the role of intracellular signalling factors, such as TNFα, IL-6, IGF-I, IGF-II and 
insulin in the development of endometrial cancer, is still unclear. It is apparent 




that link obesity with its development are still to be defined. It is also known 
that not all women who are diagnosed with endometrial cancer are obese. This 
highlights the need for further studies to identify the role that intracellular 
signalling within the adipose tissue have, in the initiation and progression of 
endometrial cancer. Identification of these pathways may allow us to possibly 
intervene to prevent cancer development. This project aims therefore, to 
partially address this lack of understanding by carrying out, in the first 
instance, a systematic review/meta-analysis of primary studies related to the 
role of adipokines and inflammatory molecules in the development of 
endometrial cancer. Subsequently a clinical study was performed in a cohort 
of patients with endometrial cancer and different BMI to assess the 
correlation(s) between these molecular markers and obesity. Blood samples 






CHAPTER 2: ADIPOCYTOKINES AND THEIR RELATIONSHIP TO 
ENDOMETRIAL CANCER RISK: A SYSTEMATIC REVIEW AND META-




The exact biological mechanism underlying the development of endometrial 
cancer is still poorly understood. In the UK, endometrial cancer is the 4th most 
common female cancer; approximately 9000 women were diagnosed with 
endometrial cancer in 2015 (Cancer Research UK, 2018). Worldwide, 320 000 
new cases of endometrial cancer were diagnosed in 2012 (Endometrial Cancer 
Report, World Cancer Research Fund, 2013). 
Obesity is a well-recognised risk factor for endometrial cancer; however, the 
relationship between obesity and endometrial cancer is complex and likely to 
involve multiple biological pathways. Sex steroid and insulin pathways, chronic 
inflammation and alterations in circulating levels of adipokines have all been 
suggested as potential mechanisms affecting endometrial cancer risk (Berstein 
et al., 2003, Slater et al., 2006, Choi et al., 2009). Elevated levels of 
endogenous oestrogens cannot justify alone the correlation between obesity 
and endometrial cancer. Moreover, experimental studies have shown that 
adipokines, associated with hyperinsulinemia and insulin resistance, and 
inflammatory cytokines, associated to increased adiposity, are also thought to 
be involved in the development of endometrial cancer (Soliman et al., 2006).  
Adiponectin, leptin, tumour necrosis factor alpha (TNFα), interleukin 6 (IL-6), 
insulin-like growth factor I and II (IGF-I and IGF-II), also collectively termed 
adipocytokines, are hormones and cytokines secreted from adipocytes; the 
major cell type of adipose tissue. Several studies have attempted to 
demonstrate an association between the risk of endometrial cancer and these 
circulating adipocytokines (Modugno et al., 2005, Wu et al., 2014). Adiponectin 
has several important functions; one of which is the regulation of insulin and 
glucose metabolism. Often described as an insulin-sensitising adipocytokine 
(Berg et al., 2001, Yamauchi et al., 2001), adiponectin promotes insulin 




facilitates the up-take of insulin in the liver by increasing peripheral tissue 
sensitivity to insulin. This is a result of increased fatty acid oxidation and the 
inhibition of glucose production from the liver (Lihn et al., 2005). Adiponectin 
also has anti-proliferative properties; it exerts its anti-tumour effects by 
activating AMP activated protein kinase (AMPK) which inhibits cell growth, 
angiogenesis and promotes apoptosis in malignant cells (Barb et al., 2007).  
Leptin affects the activity of several cell types and its main function involves 
regulating energy intake and expenditure (Daley-Brown et al., 2015). It has a 
role in glucose metabolism, as well as in the immune system. Leptin is also 
secreted by cancer cells and its levels have been reported to be increased in 
endometrial cancer and hyperplasia compared to controls with normal 
endometrium (Cymbaluk et al., 2006). 
TNFα and IL-6 are pro-inflammatory cytokines released by macrophages within 
adipose tissue and have been implicated in tumourigenesis. TNFα is an 
activator of NFκB, which promotes cellular proliferation and prevents apoptosis 
(Philip et al., 2004), whereas IL-6 initiates tumour development and 
progression through several pathways (Ara et al., 2010). Both cytokines have 
been reported to be increased in endometrial cancer (Bellone et al., 2005). IL-
6 was found to be overexpressed in the stroma of endometrial cancer cells and 
TNFα was associated with poor survival (Smith et al., 2013, Uzan et al., 2017) 
However, other studies have not reported such an increase. Chopra and 
colleagues (1997) found no difference in the expression of IL-6 in endometrial 
cancer and at the various clinical stages.  
IGF-I and IGF-II are growth factors involved in growth and development 
(Agrogiannis et al., 2014). They are expressed in the normal development of 
the endometrium and also stimulated by oestrogen in the uterus (Murphy et 
al., 1990). IGF is thought to play a role in the initiation of endometrial cancer 
due to oestrogen increasing the synthesis and expression of IGF-I which 
stimulates cell proliferation thereby initiating endometrial cancer (Majchrzak-
Baczmanska and Malinowski, 2006). An association between increased IGF-II 
expression and endometrial cancer have been reported by Pavelic and 
colleagues (2007). In their study, they found an increase in IGF-II expression 




Although evidences from in vitro and ex vivo studies for a causal role of 
adipocytokines in endometrial cancer are available, results from 
epidemiological studies are inconsistent. Meta-analyses allow for better 
estimation of the relation that exists in the population than single studies 
mainly because of the increased amount of data and statistical power. Evidence 
from epidemiological studies investigating the relationship between circulating 
adiponectin and leptin concentrations and endometrial cancer risk have been 
previously summarized in a number of meta-analyses (Gong et al., 2015, Zeng 
et al., 2015 and Lin et al., 2017), however, to date, no meta-analysis has been 
performed in to the relationship between the pro-inflammatory cytokines, TNFα 
and IL-6, or growth factors, IGF-I and IGF-II, and the risk of endometrial 
cancer. This study further clarifies the association between circulating levels of 
leptin and adiponectin, and endometrial cancer, and aimed to systematically 
assess the relationship between cytokines (IL-6 and TNFα) and the growth 
factors (IGF-I and IGF-II) levels with endometrial cancer risk via a meta-




2.2.1 Literature search 
Meta-analysis was performed and reported by adopting the Meta-analyses of 
Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al. 
2000). English-language manuscripts published between January 2000 and 
August 2018 were searched from the databases: Medline, Web of Science, 
Embase, Cochrane and CINAHL. The timeline chosen reflect the increase in 
number of publications on endometrial cancer and obesity available in the 
databases and when the searches were carried out, respectively. The following 
string of words was used for the literature search in all databases – cancer and 
endometrial and (obesity or BMI) and (adiponectin or TNF* or IGF-I or IGF-II 






2.2.2 Selection of studies and exclusion criteria 
Published studies were included if they met the following criteria: i) the study 
used an epidemiologic study design (e.g. case–control, case-cohort, nested 
case-control and cohort study); ii) the study provided information on 
circulating adiponectin, leptin, TNFα, IL-6, IGF-I, IGF-II concentrations as 
exposure of interest; iii) the study reported endometrial cancer as the outcome 
of interest; and iv) the study reported usable risk estimates (e.g. odds ratio 
(OR), risk ratio or relative risk (RR) with 95% confidence intervals (CI) between 
circulating adipocytokines levels and endometrial cancer risk). In addition, if 
more than one study was conducted in the same population, the most recent 
report or the report with the most applicable estimates was selected for 
analysis.  
Published studies were omitted by the following exclusion criteria: i) non 
epidemiological studies, reviews without original data, ecological studies, 
editorials and case reports; ii) the study reported the risk estimates that could 
not be summarized (i.e. reported the risk estimates without 95% CIs); and iii) 
the study reported exclusively on endometrial cancer mortality. All study 
selection and exclusion procedures were carried out by two independent 
investigators (P.E.E and G.B). If there was discordance, a third independent 
reviewer, G.A.B would make the final decision (authors’ initials as per 
publication). 
 
2.2.3 Data Extraction 
The following key data were extracted from each included study: first author’s 
name, publication year, study region, study design, number of cases/controls, 
assay methods, risk estimates, and matched or adjusted factors including age, 
body mass index (BMI), menopausal status, whether they have had diabetes 
mellitus (DM) or hypertension, hormone replacement therapy (HRT) usage, 
parity or whether they smoked. 
2.2.4 Statistical analysis 
Review Manager software, Version 5.0, was used to perform the meta-analysis: 




method, effect measure and analysis model, respectively. The risk estimates 
were analysed as an estimation of OR or RR for simplicity. People with the 
levels of exposure in the top tertile were compared with those in the bottom 
tertile. If the highest tertile (T3) and the lowest tertile (T1) were not available 
from the individual studies (Petridou et al., 2002, 2003; Cust et al., 2007; 
Dossus et al., 2010, 2011; Wang et al., 2011; Friedenreich et al., 2012 and 
Ohbuchi et al., 2014) then a scaling method similar to Danesh et al. (1998) 
and used by Gong et al. (2015) was used: a scaling factor of 2.18 divided by 
2.54 times the log OR for comparison of the top and bottom quartiles, or a 
scaling factor of 2.18 times the log OR for 1 standard deviation difference in 
the baseline levels of adiponectin or leptin. In addition, some of the studies 
(Soliman et al., 2006; Erdogan et al., 2013) used the highest category of 
adiponectin rather than the lower category as comparison: an effective count 
method described by Hamling and colleagues (2008) was therefore used to 
transform the comparison to the lowest tertile (T1). To assess the relationship 
between circulating adipocytokines and the risk of endometrial cancer, the 
summary of odds ratio (SOR) with 95% CI was estimated. This was performed 
using a random effect model of analysis. Chi-Squared test was used to assess 
the variation across the studies which were included in the forest plots. 
Heterogeneity across the studies was analysed using the I2 statistics (Higgins 
et al. 2002) and results were defined as heterogenous for an I2 > 50%. All 
statistical tests were two-sided. P<0.05 was considered to be statistically 
significant. 
Heterogeneity of the study results was explored by using stratified analyses 
and subgroup analyses. These analyses included design of the study, fasting 
status for the collection of the blood samples and the type of assay method 
used. Subgroup analyses to identify potential confounders included BMI, 
hypertension, diabetes and menopausal status. A variable was considered 
confounding if there were found to be significantly associated with endometrial 
cancer p<0.05 on the univariate analysis. Sensitivity analysis was performed 
to assess the influence of individual studies on the pooled OR and 95% CI by 





2.3 Results  
 
2.3.1 Search Results and publication characteristics 
The database searches identified 473 publications. A total of 427 studies were 
excluded on title and abstract review as they did not meet the inclusion criteria 
as shown in Figure 2.1. The remaining 46 studies were reviewed for further 
details and full text retrieved. Twenty-six studies were excluded for not 
containing OR values, risk ratio or relative risk with 95% CI. Therefore, a total 
of 20 articles were included in this meta-analysis, which corresponded to 18 
studies involving 2921 endometrial carcinoma cases and 5302 controls. Seven 
articles reported circulating levels for leptin, 14 for adiponectin, 3 for TNFα, 3 
for IL-6 and 1 for IGF-I. No article reported values for IGF-II. The 
characteristics of these studies, all published between 2002 and 2015, are 





















Figure 2.1 Flow diagram of screened, excluded and analysed publications 
 
Total publications identified on first screening of databases using the string 
of words: Cancer and endometrial and (obesity or BMI) and (adiponectin 
or TNF* or IGF-I or IGF-II or IL-6 or leptin) n=473 
CINAHL n=5; Cochrane n= 6; Embase n= 149; Medline n=92; Web of 
Science n=221 
Publications excluded from title and 
abstract screening n= 427 (72 abstracts, 
88 reviews, 54 cell studies, 15 animal 
studies, 145 not relevant, 53 duplicates) 
                  
 
Potentially relevant articles 
selected for full text review 
n=46 
Publications excluded as      
missing OR/RR values n=26 
                  
 
Final selection of articles that meet 
inclusion criteria n=20 (7 leptin, 































Not specified in 
text 











Q1 vs Q2 












T1 vs T3 











Not specified in 
text 
Age, BMI, nulliparity, physical 
activity, hypertension, alcohol 
consumption, hormone usage 











T3 vs T1 
Age, BMI, glucose, cholesterol, 
triglycerides, HDL cholesterol, 
insulin, adiponectin (for leptin), 































Q4 vs Q1 
Age, weight, waist to hip ratio, 
nulliparity, HRT, hypertension, 
glucose, insulin, adiponectin (for 









OR 0.6 (0.3-1.2)  
OR 2.6 (1.4-4.9) 
T3 vs T1 










T1 vs T3 









T3 vs T1 
Age, BMI, parity, education, HRT 











Age, BMI, height, education, age 
at menarche, pregnancy, IGF-I, 






84/84 Leptin (IRMA) OR 1.13 (0.70-
1.81) 
1SD increment 
Age, education, height, age at 
menarche, menopausal status, 
history of pregnancy by outcome, 















T3 vs T1 














































T3 vs T1 















T3 vs T1 
Age, HRT, current smoking status, 
family history of breast and 
endometrial cancer, education, 











Q4 vs Q1 
Age, BMI, nulliparity, age at 











OR 1.65 (0.77 - 
3.54) 
Q4 vs Q1 











Q4 vs Q1 










Q4 vs Q1 
Age, BMI, C-peptide, IGFBP-1, 




























166/315 IGF-1(RIA) OR 0.90 (0.44-
1.82) 
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menstrual cycle for pre-
menopausal women 
BMI, body mass index; WHR, waist-to-hip-ratio; ELISA ,enzyme linked immunosorbent assay; HOMA-IR, homeostasis model assessment 
of insulin resistance; QUICKI, quantitative insulin sensitivity check index; IGF, insulin like growth factor; IGFBP, insulin like growth 





Table 2.2 Summary of characteristics of endometrial cancer cases and controls for included articles 
 Cases  Controls  




































88 64.7±10.1b n/a n/a 8.29±4.07b n/a n/a n/a 90 58.7±8.6d n/a  n/a 12.43±5.34
b 




43 61.2±9.8 b 26.1±4.5b  n/a 4.91 (1.55-
13.47)g  
n/a n/a n/a 62 58.1±8.3d 23.3±3.8d n/a 7.03 (2.86-
26.06) 
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2.3.2 Adiponectin and its relationship to endometrial cancer risk 
In this current meta-analysis, fourteen studies evaluated adiponectin and its 
relationship to endometrial cancer. Two thousand and twenty-four endometrial 
cancer cases and 3,593 controls were assessed in 9 retrospective studies (8 
case control studies and, 1 cross sectional-controlled study) and 5 prospective 
studies (nested case control studies) (Table 2.1). Our combined data noted a 
significant relationship between adiponectin levels and endometrial cancer risk. 
The results suggest highest adiponectin levels compared to the lowest levels 
were significantly associated with a decreased risk of endometrial cancer. In 
particular, participants with adiponectin concentration levels in the highest 
tertile had a 0.51 times decreased risk of endometrial cancer compared to 
those women with adiponectin concentration levels in the lowest tertile, SOR 
0.51, 95% CI: 0.38-0.69. There was significant heterogeneity, I2=77% 
p<0.00001 (Figure 2.2). 
 
Figure 2.2 Forest plots of meta-analysis on the relationship between circulating 
adiponectin concentrations and endometrial cancer risk. The red squares represent the 
OR of the individual studies and the horizontal lines through the boxes represent the 
95% CI. The overall treatment effect is represented by the black diamond. 
Sensitivity analysis was performed to determine whether any particular study 
had a greater degree of influence between the association of the adiponectin 
and the risk of endometrial cancer. Omitting each study one at a time and 




CI: 0.35-0.66, I2=79%, p<0.00001) when omitting Soliman et al. (2011) study 
to 0.81 (95% CI: 0.75-0.87, I2=85% p<0.00001) when omitting Cust et al. 
(2007). No one single study had a larger influence over the other studies when 
assessing the association between adiponectin and endometrial cancer risk. 
Stratifying by study design revealed a SOR of 0.64 (95% CI: 0.41-0.99, 
p=0.06) for prospective studies and a SOR of 0.45 (95% CI: 0.29-0.68, 
p<0.00001) for the retrospective studies (Table 2.3). The heterogeneity was 
lower for the prospective studies (56%) compared to the retrospective studies 
(83%). There were variations in the type of blood samples used as well as the 
method used to measure the concentration of adiponectin. Six studies used 
fasting samples to measure adiponectin and in the other 8, it was not clear 
whether the blood samples were fasted or postprandial. The point estimate for 
studies using fasting samples was 0.56 and for the non-fasting studies, it was 
0.48. Eleven studies used an ELISA to measure adiponectin concentrations and 
3 studies used RIA/IMRA. The point estimate of SOR in the studies using the 
ELISA method was similar to the studies using RIA/IMRA (0.53 vs 0.45). When 
comparing prospective studies versus retrospective studies, there was 
significant difference in the retrospective studies (p<0.00001 vs p=0.06). 
Similarly, when comparing fasting blood samples versus non-fasting blood 
samples, the non-fasting samples were significant (p<0.00001 vs p=0.31). 
The studies using ELISA demonstrated statistical significance (p<0.00001 vs 
p=0.45).  
Raised BMI, hypertension, diabetes and menopause are all risk factors for 
endometrial cancer. Sub-analyses were performed to assess for potential 
confounding factors (Table 2.3). When considering BMI, the association 
between adiponectin levels and endometrial cancer risk is maintained (SOR 
0.49, 95% CI: 0.34-0.71, I2=79%, p=0.00001) but not for post-menopausal 
status. When considering hypertension or diabetes, a statistically significant 
association with endometrial cancers was maintained in the groups with 





Table 2.3 Summary of OR of the association between adiponectin and endometrial 
cancer stratified by study characteristics 
 Adiponectin     
No of study SOR 95% CI I2 p value 
Overall 14 0.51 0.38-0.69 77% p<0.00001 
Subgroup analyses  
Study design  
Prospective 5 0.64 0.41-0.99 56% p=0.06 
Retrospective 9 0.45 0.29-0.68 83% p<0.00001 
Fasting status      
Fasting blood samples  
Yes 6 0.56 0.42-0.74 16% p=0.31 
No 8 0.48 0.30-0.74 84% p<0.00001 
Assay method  
ELISA 11 0.53 0.38-0.57 79% P<0.0001 
RIA/IMRA 3 0.45 0.31-0.65 0% p=0.45 
BMI  
Yes 12 0.49 0.34-0.71 79% p=0.00001 
No 2 0.56 0.42-0.74 0% p=0.47 
Hypertension  
Yes 5 0.50 0.22-1.12 75% p=0.003 
No 9 0.50 0.35-0.75 62% p=0.0008 
Diabetes  
Yes 7 0.6 0.38-0.94 79% p=0.03 
No 7 0.44 0.30-0.65 60% p=0.02 
Menopausal status  
Post-menopausal 3 0.68 0.48-0.97 0% p=0.78 
 
2.3.3. Leptin and its relationship to endometrial cancer risk 
A total of seven studies; four retrospective and three prospective, assessed the 
association between circulating leptin concentrations and the risk of 
endometrial cancer (Table 2.4). Three studies were nested case controls, one 
was a hospital-based control study, one population-based case control study 
and two were case control studies. One thousand, one hundred and ninety-
nine endometrial cancers cases and 2076 control participants were assessed in 
the seven studies. The forest plot of the combined data (Figure 2.3) 
demonstrated a summary of OR of 2.19, 95% CI: 1.45-3.30, p<0.0002. These 
results suggest a significant difference between the risk of developing 
endometrial cancer in individuals with the highest leptin levels versus the 
lowest levels. Women with leptin concentrations in the highest tertile had 2.19 
times increased risk of endometrial cancer compared to the women with leptin 
concentrations in the lowest tertile. There was variation between the studies, 





Figure 2.3 Forest plots of meta-analysis on the relationship between circulating leptin 
concentrations and endometrial cancer risk. Red squares represent the OR of the 
individual studies and the horizontal lines through the boxes represent the 95% CI. 
The overall treatment effect is represented by the black diamond.  
Sensitivity analysis was performed to determine whether any particular study 
had a greater degree of influence between the association of leptin and the risk 
of endometrial cancer. Omitting one study at a time and analysing the SOR of 
the rest of the studies, the SOR ranged from 1.99 (95% CI: 1.37-2.91, 
I2=58%, p<0.0003) when omitting Wu et al. (2014) to 2.48 (95% CI: 1.89-
3.27, I2=9% p<0.00001) when omitting Friedenreich et al. (2012). No single 
study had a larger influence over the other studies when assessing the 
association between leptin and endometrial cancer risk. 
When stratifying by study design, the prospective studies had a higher SOR of 
3.32 (95% CI: 1.98-5.56, I2=15%, p=0.31) compared to the retrospective 
studies SOR of 1.67 (95% CI: 1.09-2.57, I2=56%, p=0.08). There were 
variations between the type of samples used and the measurement of leptin 
concentration; 4 studies used fasting blood samples and 3 used a post prandial 
sample. When comparing the type of samples, the point estimate of SOR for 
studies using non-fasting blood samples was higher (3.32 vs 1.67) than the 
SOR for studies using fasting blood samples. The concentration of leptin was 
either measured using an ELISA or RIA in 4 and 3 studies, respectively. In a 
further study, leptin was measured using an IMRA. The point estimate of SOR 
for studies using ELISA was 2.27 and for the studies using RIA/IMRA was 2.45. 




factors that were matched/adjusted included BMI (n=4), hypertension (n=3) 
and a history of diabetes (n=4). Table 2.4 describes the stratified analyses by 
study characteristics. When BMI is not considered, the overall association 
between leptin levels and the risk of developing endometrial cancer is not lost, 
p=0.03 (SOR 1.61, 95% CI: 0.84-3.11, I2=72%). When considering patients 
with hypertension, the overall association between leptin levels and the risk of 
endometrial cancer is maintained. The OR is not affected in comparison with 
the overall SOR (Figure 2.3) when considering patients with hypertension, 
p=0.02 (SOR 1.99, 95% CI: 0.98-4.04) and also patients with diabetes, 
p=0.01 (SOR 2.15, 95% CI: 1.23-3.76). There was significant heterogeneity 
(I2=76%) in those studies that recorded hypertension compared to those 
studies that did not (I2=42%). For those studies that recorded the presence or 
absence of diabetes in its participants, the heterogeneity was higher (I2=74%) 
compared to those studies that did not record diabetes (I2=57%).  
Table 2.4 Summary of OR of the association between leptin and endometrial cancer 
stratified by study characteristics 
 Leptin     
No of study SOR 95% CI I2 P value 
Overall 7 2.19 1.45-3.30 64% p=0.01 
Subgroup analyses  
Study design  
Prospective 3 3.32 1.98-5.56 15% p=0.31 
Retrospective 4 1.67 1.09-2.57 56% p=0.08 
Fasting blood samples  
Yes 4 1.67 1.09-2.57 56% p=0.08 
No 3 3.32 1.98-5.56 15% p=0.31 
Assay method  
ELISA 4 2.27 1.16-4.42 75% p=0.07 
RIA/IMRA 3 2.45 1.67-3.59 0% p=0.45 
BMI  
Yes 4 2.69 1.76-4.12 27% p=0.25 
No 3 1.61 0.84-3.11 72% p=0.03 
Hypertension  
Yes 3 1.99 0.98-4.04 76% p=0.02 
No 4 2.42 1.47-3.97 42% p=0.16 
Diabetes  
Yes 4 2.15 1.23-3.76 74% p=0.01 
No 3 2.43 1.03-5.69 57% p=0.10 
Menopausal status  




2.3.4 TNFα, IL-6 and IGF-I and their relationship to endometrial cancer 
risk 
The paucity of studies analysing TNFα, IL-6 and IGF-I and their association 
with the risk of endometrial cancer is evident (Tables 2.1 and 2.2). Two studies 
(one prospective and one retrospective) assessed both TNFα and IL-6 in a 
single cohort and a further 2 studies (both prospective) assessed TNFα and IL-
6 only. There was only one study (prospective) investigating the role of IGF-I 
and the risk of endometrial cancer. The total number of endometrial cancer 
and control cases for TNFα was 940 and 1781 respectively, and for IL-6, it was 
975 and 1837, respectively. The prospective study assessing IGF-I and its 
correlation with endometrial cancer risk had 166 cases and 315 controls. From 
the meta analyses, there appeared to be no association between circulating 
levels of TNFα and IL-6 and overall risk of developing endometrial cancer 
(SOR=1.30, 95% CI: 0.87-1.95, SOR=1.21 95% CI: 0.85-1.72 respectively) 
(Figures 2.4 and 2.5). 
Heterogeneity was present for TNFα studies but not for IL-6 studies (p=0.06 
and I2=65% for TNFα and p=0.14 and I2=48% for IL-6).  
 
Figure 2.4 Forest plots of meta-analysis on the relationship between TNFα 
concentrations and endometrial cancer risk. The red squares represent the OR of the 
individual studies and the horizontal lines through the boxes represent the 95% CI. 






Figure 2.5 Forest plots of meta-analysis on the relationship between IL-6 
concentrations and endometrial cancer risk. The red squares represent the OR of the 
individual studies and the horizontal lines through the boxes represent the 95% CI. 
The overall treatment effect is represented by the black diamond. 
Sensitivity analysis was performed to determine whether any single study had 
a greater degree of influence between the association of TNFα and the risk of 
endometrial cancer. When Wang et al. (2011) was excluded, the SOR was 1.26 
(95% CI: 0.74-2.14, I2=79%, p=0.03); excluding the study performed by 
Freidenreich et al. (2013), the SOR was 1.66 (95% CI: 1.14-2.43, I2=0%, 
p=0.77) and finally excluding the study performed by Dossus et al. (2011), the 
SOR was 1.09 (95% CI: 0.78-1.53, I2=33%, p=0.27). There are differences 
between the 3 studies which could explain the change in SOR; the Wang et al. 
study was a prospective study and the studies by Friedenreich et al. (2013) 
and Dossus et al. (2011) were retrospective and prospective studies, 
respectively. The participants in the Wang et al. (2011) study were 
postmenopausal women who were not using any hormone treatments. Both 
pre- and post–menopausal women were included in the other 2 studies and 
some participants in these 2 studies were also noted to be using hormones. 
Sensitivity analysis was also performed to determine whether any single study 
had a greater degree of influence between the association of IL-6 and 
endometrial cancer risk. The SOR ranged from 1.08 (95% CI: 0.8-1.46, 
I2=10%, p=0.290, when omitting the Dossus et al. (2010) to a SOR of 1.32 
(95% CI: 0.93-1.88, I2=52% p=0.15), when excluding the Wang et al. (2011) 
study. Excluding the Friedenreich et al. (2013) study, the SOR was 1.19 (95% 






Inflammation, an important factor in the development and progression of 
cancer has been implicated in the link between obesity and cancer (Arendt et 
al., 2013; Bowers et al., 2015). Adiponectin, leptin, TNFα, IL-6 and IGF-I are 
biological factors that are involved in different stages of the inflammatory 
pathway. The aim of the present meta-analysis was to further clarify the link 
between adiponectin and leptin and endometrial cancer risk, and to assess the 
association between TNFα, IL-6, IGF-I and IGF-II and endometrial cancer risk 
by conducting a systematic review and meta-analysis of the published 
literature. The paucity of studies reported in the literature investigating the link 
between the adipocytokines and endometrial cancer is evident; between 2000 
and 2018, only 20 publications were found in the literature that met the 
inclusion criteria set. Undertaking a systematic review and meta-analysis 
increased the population size which would enhance the accuracy and precision 
of the findings from the various studies. This would allow a greater 
understanding of the association between adipocytokines and endometrial 
cancer risk. Our analysis concurred with other reported studies (Luhn et al., 
2013; Ma et al., 2013) on the association between adiponectin and leptin 
concentration levels and endometrial cancer risk: increased adiponectin serum 
levels and decreased leptin levels are associated with an overall decreased risk 
of endometrial cancer. It was found that women with higher levels of 
adiponectin had the risk of developing endometrial cancer decreased by half 
compared to those women with lower levels of adiponectin. Women with high 
levels of leptin had a two-fold increased risk of developing endometrial cancer 
compared to women with low levels of leptin. The studies reported by Dallal et 
al. (2013) and Soliman et al. (2011) did not find an association between 
adiponectin serum levels and endometrial cancer risk. Due to the increased 
numbers of cases and controls obtained in our meta-analysis, our findings are 
more robust compared to the single studies performed by Dallal et al. (2013) 
and Soliman et al. (2011). In addition, both studies were prospective, and 
slight differences between the prospective and retrospective studies were 
highlighted by the sub analyses carried out (Table 2.3). For adiponectin, the 
SOR was 0.64 for prospective studies compared to 0.45 for retrospective with 




SOR for prospective studies was 3.32 compared to 1.67 for retrospective 
studies. 
The meta-analysis of the studies assessing IL-6 and TNFα did not demonstrate 
an association with endometrial cancer risk. Despite the limited number of 
studies, the number of endometrial cancer cases and controls were relatively 
high; 975 vs 1837 and 940 vs 1781 cases vs controls, respectively. However, 
when assessing the individual studies, Dossus et al. (2011), reported elevated 
levels of TNFα was significantly associated with an increased risk of endometrial 
cancer amongst women in the highest quartile compared to the lowest quartile. 
Similarly, Dossus et al. (2010) reported an increased risk of endometrial cancer 
with elevated levels of IL-6 whereas the studies conducted by Wang et al. 
(2011) and Friedenreich et al. (2013) did not find an association between TNFα 
and IL-6 and the risk of endometrial cancer. It is unclear why the findings of 
these studies were inconsistent in relation to the risk of endometrial cancer 
and levels of TNFα and IL-6. All the studies used ELISA to measure TNFα and 
IL-6. Both the studies conducted by Dossus et al. (2010; 2011) had pre-
menopausal women (25% and 18.5% in the 2010 and 2011 studies, 
respectively) in their endometrial cancer cases. The average BMI of the cases 
in the studies was 27.5 kg/m2 and 28.1 kg/m2, respectively. The number of 
cases in the studies with a history of diabetes was very small; 4.6% and 3.4%, 
respectively. A history of hypertension was not recorded in either studies. The 
study conducted by Wang et al. (2011), included only post-menopausal women 
and non-users of hormones. The average BMI was 30 kg/m2. A history of 
hypertension or diabetes was not recorded in the study. Friedenreich et al. 
(2013) consisted mainly of perimenopausal and post-menopausal women 
(89.4%) and 44.5% users of HRT. In their study, the average BMI was 32.3 
kg/m2 and 32% of the cases had a history of hypertension. A history of diabetes 
was not recorded. It appears that BMI, menopausal status or a history of 
diabetes/hypertension does not influences the association of TNFα or IL-6 and 
endometrial cancer risk. 
Further sub-analyses were performed to identify any other factors that could 
affect the risk of endometrial cancer. Tables 2.3 and 2.4 summarises the OR 
of the association between circulating adiponectin, leptin and endometrial 




association between circulating adiponectin levels and endometrial cancer risk, 
but not with circulating leptin levels and endometrial cancer risk. Hypertension 
and diabetes appear to affect the association between circulating leptin levels 
and increased endometrial cancer risk. The presence or absence of 
hypertension and diabetes appeared to affect the association between 
circulating adiponectin levels and endometrial cancer risk. Adiponectin and 
leptin may act synergistically and increase the risk of endometrial cancer. This 
is not the case for TNFα and IL-6.  
The strength of this meta-analysis is that it presents a relatively comprehensive 
review of the existing evidence on the association of various adipocytokines 
and endometrial cancer. In particular, stratified analysis using a variety of 
selected variables has strengthened the results against the influence of 
confounding factors. There were limitations to the meta-analysis; the number 
of cases in each study was relatively small, however the overall number of 
endometrial cancer cases in the meta-analysis was high, 2921, and the timeline 
selected for the searches could have been increased in order to include more 
studies. Retrospective studies were included and therefore, there is always a 
risk of potential bias in the form of recall bias.  
Our meta-analysis was the first to assess 5 adipocytokines in relation to 
endometrial cancer risk. Larger prospective studies assessing the 5 
adipocytokines are required to investigate further the association between 
adipocytokines and endometrial cancer. This would allow us to elucidate in 
more details, the exact mechanisms underlying the link between 
adipocytokines and endometrial cancer.  
In chapter 3, 6 adipocytokines in blood samples taken from a cohort of patients 




CHAPTER 3: CIRCULATING LEVELS OF ADIPOCYTOKINES IN WOMEN 
WITH ENDOMETRIAL CANCER 
 
3.1 Introduction 
Chronic low-grade inflammation is generally accepted to initiate the 
development of cancer due to the genetic damage caused by the release of 
reactive oxygen and nitrogen species. These species induce the formation of 
mitogenic adherent DNA lesions. This theory forms part of the intrinsic pathway 
mechanism where tumour cells stimulate the release of local inflammatory 
mediators promoting tumour growth and progression (Mantovani et al., 2009). 
Inflammatory mediators can concomitantly affect endometrial cancer risk by 
promoting insulin resistance, hyperglycaemia and increase the production of 
oestrogen within the adipose tissue and the endometrium (Greenberg et al., 
2002; Purohit and Reed, 2002; Dossus et al., 2012; Shaw et al., 2016). 
Adipocytokine related signalling pathways are important in the development of 
an inflammatory microenvironment for tumours. This process is thought to 
increase the risk of endometrial cancer by inducing cell proliferation and the 
production of free radicals (Shaw et al., 2016). It has also been observed that 
adipocytokines can indirectly inhibit the DNA damage repair system and 
apoptosis (Pucino et al., 2014). Several studies have demonstrated an 
association between the risk of endometrial cancer and single circulating 
adipocytokines (Lukanova et al., 2004; Friedenreich et al., 2013; Gong et al., 
2015). However, no study to date has been carried out to assess the 
association of several adipocytokines together in the same patient population 
and in relation to their obesity status.  
 
3.2 Aim  
To assess the circulating levels of adiponectin, leptin, tumour necrosis factor 
alpha (TNFα), interleukin 6 (IL-6), insulin-like growth factor I (IGF-I) and II 
(IGF-II) in serum from women with endometrial cancer and to determine 





3.3 Materials and Methods 
 
3.3.1 Blood specimens 
In 2018, patients from the Royal Surrey County hospital, with a new diagnosis 
of confirmed endometrial cancer, were invited to take part in the retrospective 
study titled “Discovering new cancer biomarkers from patient’s blood, urine 
and DNA” (study Number 08/H1306/115). Ethical approval was granted by the 
Royal Surrey Hospital. Patient information sheet and consent form are 
documented in the appendix. 
Blood samples were taken on the morning of surgery from patients undergoing 
a Da Vinci robotic assisted hysterectomy and bilateral salpingo-oophorectomy 
with or without pelvic lymph node sampling. The blood samples were 
immediately processed by centrifugation and serum stored at – 80°C at the 
University of Surrey. Serum samples from twenty-four patients with a 
diagnosis of endometrial cancer, one with endometrial hyperplasia and 2 
control participants without endometrial cancer or hyperplasia, were collected 
and analysed for circulating levels of adiponectin, leptin, TNFα, IL-6, IGF-I and 
IGF-II.  
Patient history and clinical examination were recorded for all patients. Data 
collected on clinical characteristics included age, BMI, type of endometrial 
cancer, menopausal status and any medical conditions, such as, hypertension 
or diabetes. Where possible, white cell counts (WCC) and C-reactive protein 





3.3.2 ELISA  
Sandwich ELISA (enzyme-linked immune-sorbent assay) is a very useful tool 
in quantifying antigens and requires the use of a capture antibody, specific for 
an antigen, bound to a microplate well. The protein mixture is added to the 
well and the specific antigen binds to the capture antibody. After several 
washes to remove any nonspecific binding, a detection antibody, linked to 
biotin, is added. Following the removal of the excess detection antibody 
through repeated washes, Streptavidin-Horse Radish Peroxidase (HRP) 
conjugate is then added that binds to the detection antibody. Subsequently, a 
substrate is added, which is then converted by the HRP enzyme to form a 
colour signal. The intensity of the colour signal within the final product is 
proportional to the concentration of antigen present in the original sample and 
is measured using a microplate reader. 
Adipocytokines were measured using a standard ELISA protocol, following 
manufacture guidelines: human Adiponectin (DY1065); human Leptin 
(DY398), human TNFα (DY210), human IL-6 (DY206), human IGF-I (DY291) 
and human IGF-II (DY292) (Biotechne, UK). 
A capture antibody specific to each adipocytokine was first dissolved in 
phosphate buffer saline (PBS) without carrier protein and then diluted to a final 
working concentration (Table 3.1). One hundred µl of diluted capture antibody 
were then added per well in a 96-well microplate. The plate was sealed and 
incubated overnight at room temperature. Each well was aspirated and washed 
3 times with 300 µl wash buffer (0.05% Tween 20 in PBS) using a multichannel 
pipette. At each step, the wash was completely removed by tapping the plate 
and blotting it on paper towels. Reagent diluent (300 µl) was added to each 
well to block any non-specific binding and left at room temperature for 1 hour. 
A further 3 washes were performed as before with wash buffer in preparation 
for the addition of samples or standards (Table 3.1). 
One hundred µl of standard (Table 3.1) or samples were added to each well, 
covered and incubated for 2 hours at room temperature. The standards and 
samples were aspirated and the wells washed (x3) as previously stated. This 
was followed by the addition of the detection antibody (100 µl), diluted in 




incubated for two hours. A repeated aspiration and wash (x3) were performed. 
One hundred µl of Streptavidin–HRP (Table 3.2) was added to each well and 
incubated for 20 minutes at room temperature, covered in foil to avoid 
exposure to light. 
Table 3.1 Details of the capture antibodies, the concentration range of standards and 









































Table 3.2 Details of the detection antibodies concentration, Streptavidin HRP and 












Adiponectin 180 µg/ml 1 µg/ml 1:200 
1% BSA in 
PBS* 
Leptin 1.5 µg/ml 25 ng/ml 1:40 
1% BSA in 
PBS* 
TNFα 90 µg/ml 500 ng/ml 1:200 
1% BSA in 
PBS* 
IL-6 9 µg/ml 50 ng/ml 1:200 
1% BSA in 
PBS* 
IGF-I 9 µg/ml 150 ng/ml 1:40 
5% Tween20 
in PBS* 
IGF-II 12 µg/ml 200 ng/ml 1:40 
5% Tween20 
in PBS* 
*PBS pH 7.2-7.4 
This was followed by a repeat aspiration and wash (x3), and then the addition 
of 100 µl substrate solution (substrate solution A and B). Plate was covered 
with foil and incubated again for 20 minutes at room temperature. Finally, 50 
µl Stop Solution was added to each well. The optical densities of the standards 
and samples were obtained using a microplate reader (BioTek, UK) set to 450 





3.3.3 Statistical analysis 
A two-tailed t test, using EXCEL 2016, was used to assess the differences 
between the groups. A p<0.05 was considered statistically significant. The 
percentage change in adipocytokine levels was described and calculated by 
comparing the average adipocytokine concentration levels in the obese and 
OW groups and comparing it to the adipocytokine levels in the NW groups. The 




3.4.1 Participant characteristics 
Twenty-four patients with a diagnosis of endometrial cancer, one with 
endometrial hyperplasia and 2 patients without endometrial cancer were 
included in this study. Participant characteristics were recorded for obese, 
overweight (OW) and normal weight (NW) cases with endometrial cancer and 
endometrial hyperplasia (Table 3.3) and control participants without 
endometrial cancer (Table 3.4). A history of hypertension or diabetes and the 
use of HRT were also recorded. The average age of the women with 
endometrial cancer was 69 ± 2 years old. 
Seventy-two percent of the women with endometrial cancer had Type 1 
(endometrioid) endometrial cancer. All except one case had stage I or II 
disease. The average age of the obese and OW cases was 71 ± 2 years and 70 
± 2 years respectively and the average BMI was 37.1 ± 1.7 kg/m2 and 27.3 ± 
0.6 kg/m2, respectively. The NW cases were younger compared to the other 
weight categories with an average age of 59 ± 9 yeas and average BMI of 21.8 
± 1.1 kg/m2. There was a significant difference between the age of the obese 
cases and the NW cases (p=0.025) but not when comparing the OW cases with 
the NW cases (p=0.225). One explanation for the increasing age in the obese 
group could be due to the fact that, as we become older, most people gain 




men and women and also chronic illnesses such hypertension, diabetes and 
cardiovascular disease (Zhen et al., 2017). The control cases had an average 
age of 66.5 years and BMI of 28.1 kg/m2 (n=2).  
Within the obese category, 4 out of 16 cases had hypertension and 3 out of 16 
had diabetes. One of the obese cases had both co-morbidities. In the 
overweight group, 3 out of 5 patients had hypertension and 2 out of 5 had 
diabetes. Two of the cases described in the overweight group had both co-
morbidities. The 4 NW cases had neither hypertension nor diabetes. One out 
of the 2 control cases had both co-morbidities. WCC and CRP levels were 
analysed in each patient to assess signs of inflammation and thus linking 
chronic inflammation to the development of endometrial cancer. Two out of the 
16 obese cases had a raised CRP of 14 mg/L and 32 mg/L, respectively (normal 
level <10 mg/L) and one of the 5 NW cases also had a raised CRP of 20 mg/L. 
The OW cases and the control cases did not have raised CRP levels and none 
of the cases in any of categories or control cases had raised WCC (normal range 
=4-11 mg/L). Twenty three patients did not use HRT. One patient used HRT in 
the form of local oestrogens in the vagina and for the remaining patient, we 
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Control 
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65 32 10.9 4 Yes Yes PM No 
Control 
2 
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3.4.2 Circulating levels of adipocytokines 
The concentration levels of the adipocytokines in the obese, OW and NW 
patients are presented in Figures 3.1 to 3.6. Serum levels of the individual 
adipocytokines are compared between each BMI category.  
The mean adiponectin concentration was 2.30 ± 0.15 µg/ml for the obese 
cases, for the OW cases, the mean concentration was 2.2 ± 0.12 µg/ml and 
for the NW cases patients, it was 2.26 ± 0.14 µg/ml (Figure 3.1). 
 
Figure 3.1 Adiponectin levels in different weight categories in cancer patients. Results 
are presented as mean±standard deviation. Obese group n=16, overweight group 
(OW) n=5, normal weight group (NW) n=4. 
When comparing these results with the adiponectin level in the NW cases, there 
was a 1.8% increase in the obese cases and a 2.6% decrease in the OW cases. 


























concentration levels in the obese category and the NW category and between 
the OW group and the NW group (p=0.56). 
Leptin concentration was statistically significantly higher (p=0.0065) in the 
obese group compared to the NW group and when compared to the OW group 
(p=0.0039). No significant differences were observed when comparing the OW 
group to the NW group (p=0.55). In the obese group, leptin concentration level 
was 59.41 ± 28.72 ng/ml, 16.23 ± 5.19ng/ml in the OW group and 14.30 ± 
3.67 ng/ml in the NW group (Figure 3.2). 
 
Figure 3.2 Leptin levels in different weight categories in cancer patients.  
Results are presented as mean± standard deviation. Obese group n=16, overweight 
group (OW) n=5, normal weight group (NW) n=4. p= 0.0065 in the obese group 
compared to the NW group. p=0.0039 in the obese group compared to the NW group. 
This equated to an increase of 315% in leptin concentration levels in the obese 
cases and 13.6% increase in the OW group when compared to the NW group. 
TNFα levels were significantly higher in the obese category compared to OW 
group (p=0.01). In the obese cases, the mean TNFα level was 704 ± 459.7 
pg/ml, in the OW group, it was 78.54 ± 15.85 pg/ml. There was only one value 
obtained for the NW group, which was 216 pg/ml (Figure 3.3). When comparing 
the change in TNFα mean concentrations between the obese and the NW 
groups, there was 226% increase in the concentration levels but a decrease of 



























Figure 3.3 TNFα levels in different weight categories in cancer patients.  
Results are presented as mean± standard deviation. Obese group n=16, overweight 
group (OW) n=5, normal weight group (NW) n=4. 
 
IL-6 mean concentration levels in the obese category were also higher 
compared to the other groups but no statistical comparison could be made as 
only one value was available in the OW and NW groups respectively. The 
concentrations were 182.45 ± 188.99 pg/ml in the obese group, 2.42 pg/ml 
and 0.6 pg/ml in the OW and NW groups, respectively (Figure 3.4).  
 
Figure 3.4 IL-6 levels in different weight categories in cancer patients.  
Results are presented as mean± standard deviation. Obese group n=16, overweight 
group (OW) n=5, normal weight group (NW) n=4. IL-6 concentrations were below 



















































IGF-I mean concentration levels in the obese and OW groups demonstrated an 
increase when compared to the mean concentration of IGF-I in the NW group. 
In the obese and OW groups, the IGF-I concentrations were 948.57±984.58 
ng/ml and 376.25 ± 150.26 ng/ml respectively. There was a statistical 
difference (p=0.04) between the IGF-I levels in the obese cases compared to 
the OW group. There was only one value (11.5 ng/ml) in the NW group and 
therefore no statistical comparison could be made (Figure 3.5). 
 
Figure 3.5 IGF-I levels in the different categories in cancer patients.  
Results are presented as mean± standard deviation. Obese group n=16, overweight 
group (OW) n=5, normal weight group (NW) n=4. p=0.04 between the obese category 
and OW group. 
As demonstrated for IGF-I, a similar increase in IGF-II concentrations were 
also noted in the obese and OW groups when comparing the concentration 
levels to the single value of 13.21 ng/ml in the NW group. In the obese and 
OW groups, the IGF-II concentrations were 4200 ± 3745 ng/ml and 733 ± 943 
ng/ml, respectively. The difference between IGF-II levels in the obese group 



























Figure 3.6 IGF-II levels in the different weight categories in cancer patients. Results 
are presented as mean± standard deviation. Obese group n=16, overweight group 
(OW) n=5, normal weight group (NW) n=4. IGF-II concentrations were below detection 
levels in serum of NW patients. p=0.049 between the obese category and OW group. 
 
3.5 Discussion  
Women with endometrial cancer have been reported to have a higher incidence 
of cardiovascular disease risk factors compared to women in the general 
population (Felix et al., 2010). Hypertension and diabetes are independent risk 
factors for endometrial cancer and women with diabetes have a 2–fold 
increased risk of developing endometrial cancer compared to women without 
diabetes (Kitson et al., 2018). In the current study, 28% and 20% of women 
with endometrial cancer/ hyperplasia had hypertension and diabetes, 
respectively. It was also noted that 63% of the obese patients had Type 1 
endometrial cancer which increased to 80% of patients in the OW group and 
100% in the NW group. 
This observation is in contradiction to the general theory that suggests the 
aetiology of Type 1 (endometrioid) endometrial cancers is the result of excess 
oestrogen production in the adipose tissue, stimulating neoplastic growth in 
the endometrial lining (Britton et al., 2016), however, the numbers (25) are 
too small to draw any clear conclusions from these findings. 
It has been reported that there is an association between CRP concentrations 





























evidence can be drawn from studies on colorectal cancer (Tsilidis et al., 2008; 
Pendyala et al., 2011). Zhou and colleagues (2014) reported, in their meta-
analysis of 18 studies, a higher risk of colon cancer with increasing 
concentration of CRP. However, they did not assess the association between 
colon cancer CRP and different BMI. To our knowledge, there has been no study 
which has assessed the relationship between CRP, WCC concentrations and 
endometrial cancer risk. In our study, the highest CRP level above the normal 
threshold of 10 mg/L, were higher in the obese category (32 mg/L compared 
to 9.7 mg/L and 20 mg/L in the OW and NW groups, respectively). 
In the obese state, hypertrophic adipocytes secrete abnormal levels of pro 
inflammatory cytokines, which include TNFα and IL-6, with a decrease 
production of anti-inflammatory markers such as adiponectin (Smitka et al., 
2015). The anti-inflammatory properties of adiponectin are well characterised; 
it promotes the secretion of anti-inflammatory cytokines such as IL-10 and IL-
1 receptor antagonist and reduces the production of TNFα (Wolf et al., 2004). 
Adiponectin levels are reduced in the obese state, which in turn further increase 
the pro-inflammatory cytokines, TNFα and IL-6. Adiponectin levels are also 
reduced in postmenopausal women as well as in chronic illnesses such as 
hypertension, diabetes and coronary artery disease (Mather et al., 2014; 
Riestra et al., 2015; Lai et al., 2015). 
In this current study, adiponectin levels in the obese patients did not correlate 
with the results observed in other studies in the literature (Cust et al., 2007; 
Ashizawa et al., 2010). There was no significant difference (p=0.63 in the 
obese vs NW and in the OW vs NW, p=0.56) in adiponectin levels amongst the 
different weight categories in the endometrial cancer patients. Increasing BMI 
was associated with decreasing adiponectin levels (p<0.0001) which was also 
associated with endometrial cancer cases in the study conducted by Cust et al. 
(2007). In their study, the mean adiponectin concentration was 8.4 µg/ml in 
the endometrial cancer cases and 9.9 µg/ml in the control cases. In their obese 
cancer group, adiponectin levels were 6.6 µg/ml, 8.6 µg/ml in the OW and 10.4 
µg/ml in the NW groups. In the current study, the mean adiponectin 
concentration levels in the endometrial cancer cases was 2.27 µg/ml, 2.3 µg/ml 
in the obese group, 2.2 µg/ml in the OW and 2.26 µg/ml in the NW categories. 




women with endometrial cancer had significantly lower adiponectin levels (6.2 
± 0.4 µg/ml) in the endometrial cancer cases, than in the control (9.0 ± 0.4 
µg/ml), (p<0.0001). Adiponectin levels significantly correlated with BMI 
(p<0.05). In the current study, the adiponectin levels in the endometrial 
cancer cases were low which supports the hypothesis that lower adiponectin 
levels are associated with increased risk of endometrial cancer. It is worth 
noting that, in different cancers, studies have reported findings similar to our 
results i.e. no differences in the levels of adiponectin and different categories 
of BMI in cancer patients. Serratta et al. (2019) did not find any differences in 
the association between BMI and circulating levels of adiponectin and leptin in 
prostate cancer. The lack of differences between levels in different BMI 
categories could be due to a number of factors; 84% of our patients were in 
the obese and OW groups. Our findings may be due to a relatively homogenous 
group of patients underpowering the study for a relatively small number of NW 
patients. Also, except for one patient, all the women with endometrial cancer 
had reached menopause and an average age of 69 ± 2 years. The oldest 
endometrial cancer cases were in a study conducted by Dallal et al. (2013), 
mean age 67.4 ± 5.5 years and the youngest endometrial cancer cases were 
in the study by Wu et al. (2014), mean age 44.3 ± 8.5 years. Adiponectin 
levels are known to be reduced in postmenopausal women due to the aging 
process (Mathers et al., 2014). The different assay techniques used for 
determination of adiponectin concentration compared to other studies may 
have also influenced the results: Petridou et al. (2003) and Dal Maso et al. 
(2004) used RIA to measure adiponectin concentrations. Interestingly, Ma et 
al. (2013) also had the same adiponectin levels in their endometrial cancer 
cases. Their mean adiponectin levels in the endometrial cancer cases were 2.33 
µg/ml. In the current study, it was also 2.3 µg/ml. Both studies used an ELISA 
to measure adiponectin levels and the study design was retrospective in each 
study. However, the mean age of the endometrial cancer patients was 
different; 53.2 years in the Ma et al. (2013) study and 69 years in the current 
study. 
In the present study, adiponectin levels were measured after the diagnosis of 
endometrial cancer was made rather than prior to diagnosis. The effect of the 




unknown. Moreover, all patients participated in the enhanced recovery 
programme (ERP) before surgery. ERP is an evidence based modern approach 
that all patients undergoing major surgery take part in. It helps people to 
recover more quickly after surgery. It requires all patients undergoing major 
surgery, taking a preloaded glucose drink the night before and on the morning 
of their surgery. It is well recognised that a person’s nutritional status and or 
body weight can influence the serum concentration levels of adiponectin (Kopp 
et al., 2005; Agra et al., 2018). The glucose preload that patients are required 
to drink may have an indirect effect on the serum levels of adiponectin. It is 
known that adiponectin reduces glucose production in the liver by decreasing 
the levels of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase 
gene expression (Lihn et al., 2005). What is not clear is the effect of a sudden 
surge of high levels of glucose in the form of the pre-load that patients are 
required to take before surgery, has on adiponectin levels. As ERP is a relatively 
new approach in surgery, it is unlikely patients in previous studies, would have 
participated in this programme. 
Leptin plays a dynamic role in the regulation of appetite and energy 
expenditure and its secretion is dependent on the status of both these 
metabolic processes. It is widely accepted that leptin levels are increased in 
the obese state (Fredman and Halaas, 1998). Increased leptin levels promote 
low grade inflammation by elevating levels of IL-6 and TNFα within the adipose 
tissue microenvironment (Cabone et al., 2012 Strong et al., 2015). IL-6 has 
been shown to promote the release of CRP by the liver, further enhancing a 
state of chronic low-grade inflammation (Pasceri et al., 2000). Due to this 
effect of promoting an inflammatory state, raised leptin levels indirectly 
increase the risk of endometrial cancer by promoting cell proliferation and the 
release of free radicals that cause DNA damage (Coussens et al., 2002). Our 
results correlate with the findings of Cymbaluk et al. (2008); leptin levels were 
higher in the obese endometrial cancer patients compared to the OW and NW 
patients. In their study, Cymbaluk and colleagues assessed leptin serum levels 
in 86 obese post-menopausal women with endometrial cancer and hyperplasia 
and 40 controls. The obese women were subdivided into different BMI 
categories. The mean serum leptin level was 16737.1 pg/ml in the endometrial 




correlation between serum leptin concentration and BMI. Significantly higher 
concentration levels of leptin (p<0.005) was reported with increasing BMI 
compared to the control group.  
Increasing IL-6 levels have been reported to correlate with increasing BMI 
(Yudkin et al., 1999). IL-6 is also a stimulator of aromatase activity which 
increases the production of oestrogen in the adipose tissue (Zhao et al., 1995) 
and may increase and promote the development of endometrial cancer. In the 
current study, IL-6 circulating levels increased with increasing weight. It was 
higher in the obese category compared to the OW and NW groups. Similarly, 
TNFα was also higher in the obese category compared to the OW group. Leptin, 
TNFα and IL-6 were all increased in the obese cases which would support the 
evidence that leptin promotes low grade inflammation by increasing TNFα and 
IL-6 levels within the adipose tissue (Cabone et al., 2012 Strong et al., 2015). 
However, Wang et al. (2011), in their prospective study, did not report similar 
results; TNFα and IL-6 did not correlate with increasing BMI or endometrial 
cancer risk. It is unclear why there are conflicting results. Both the current 
study and the one by Wang et al. (2011) had endometrial cancer cases of a 
similar average age range and similar menopausal status. Both studies used 
ELISA to measure TNFα and IL-6 concentrations. One difference noted was that 
the Wang et al. (2011) study was a prospective study and the current study 
was a retrospective one which could explain the different results in each study. 
It is known that prospective studies reduce the occurrence of “reverse 
causation bias” and therefore the cancer cells could have modified the levels 
of the TNFα and IL-6 in the current study.  
The overall number of studies assessing the associations between TNFα and 
IL-6 with obesity and endometrial cancer is small. Increasing the number of 
prospective studies, on assessing the association between obesity related 
endometrial cancer and these two pro-inflammatory cytokines, would enhance 
our knowledge further. 
There have been conflicting reports in the literature regarding IGF-I and IGF-
II levels in the obese state (Frystyk et al., 1995; Ricart et al., 2001; Gomez et 
al., 2004; Nam et al., 2014). IGF-I and IGF-II have important roles in growth 




between IGF-I and IGF-II, endometrial cancer risk and the development of 
endometrial cancer is not well understood. IGF-I and IGF-II have been reported 
to be involved in the progression of endometrial cancer (Pavelic et al., 2007). 
Liang et al. (2012) reported higher IGF-I and IGF-II mRNA levels in tumour 
tissues and tumour adjacent tissues than in the control cells. Increased 
production of IGF-I in the liver is a result of hyperinsulinemia in the obese 
state. IGF-I is dependent on growth hormone secretion, which in turn is 
reduced in obesity; this would imply a reduction in IGF-I levels. However, it 
has been reported that total IGF-I levels remain the same due to increased 
hepatic sensitivity to growth hormones (Lewitt et al., 2014). Lukanova et al. 
(2004) reported no association between endometrial cancer risk and IGF-I 
levels. Their IGF-I levels in the endometrial cancer cases were lower: 169 
ng/ml compared to our cases, which was 202.85 ng/ml. The study design of 
Lukanova et al. (2004) was prospective with an average age of the endometrial 
cancer cases of 61 years and a mean BMI of 27.3 kg/m2. In the current study, 
the average age was 69 years and the mean BMI 32.7 kg/m2. The mean 
concentration levels of IGF-I were raised in the obese and overweight 
categories compared to the normal weight and control. There was significant 
difference (p=0.04) between the obese and the OW groups. This could be due 
to the presence of hyperinsulinemia in the obese and OW groups, which would 
result in an increased production of IGF-I. This would account for the raised 
levels of IGF-I; however, only 3 of the 16 obese patients had diabetes and 2 
out of the 4 patients in the OW group. None of the NW patients had diabetes. 
It could be argued that this is the result of the patients ingesting a glucose pre-
load in the evening prior to surgery and in the morning of their operations. 
However, as the mean concentration levels of IGF-I in the NW group was 
similar to the control participants; this explanation for the higher levels of IGF-
I is unlikely. The relationship between IGF-II and obesity and endometrial 
cancer risk is less clear. To our knowledge, there is no study in the literature 
that assesses the relationship between IGF-II and endometrial cancer in 
different weight categories. Frystyk et al. (1995) conducted a study which 
involved 92 (56 males, 36 females) healthy subjects and measured free serum 
and total IGF-II and IGF-I levels in obese cases. The participants were allocated 
to 3 groups depending on body BMI: 31 controls (BMI<25 kg/m2), 33 subjects 




obesity (BMI >30 kg/m2). Total IGF-II levels were increased in the obese 
subject (p>0.05) but the serum free IGF-II levels were unaltered in the obese 
state. In the current study, IGF-II levels were found to be increased in the 
obese state. There was a significant difference (p=0.04) between the obese 
group and the OW group. 
Work conducted by the Bermano group (unpublished work) at Robert Gordon 
University, assessed the adiponectin, leptin, TNF-α and IL-6 concentration 
levels in twenty-two female volunteers: 6 obese, 6 OW and 10 NW cases. The 
mean age and BMI in the obese cases was 30.2 ± 5.4 years of age and the 
BMI 40.5 ± 2.5 kg/m2; for the OW cases, it was 26.7 ± 5.6 years of age and 
the BMI 27.1 ± 1.6 kg/m2; and the NW cases, 23.9 ± 4.8 years of age and the 
BMI 22.2 ± 1.5. The average adiponectin level in the obese cases was 9.98 ± 
5.60 µg/ml; for the OW group it was 10.7 ± 6.18 µg/ml and for the NW group, 
it was 12.07 ± 8.27 µg/ml. Comparing these data to the current study findings, 
adiponectin levels were lower in the obese cancer cases (2.3 ± 0.15 µg/ml). 
The lower levels of adiponectin in the obese, OW and NW endometrial cancer 
cases compared to the healthy volunteers adds further to the argument that 
lower levels of adiponectin is associated with obesity and endometrial cancer. 
It is noted that the average age in the endometrial cancer cases, in the current 
study, is 69 years of age and it is known that adiponectin levels are reduced in 
postmenopausal women due to the process of ageing (Mathers et al., 2014). 
However, a recent study by Wang et al. (2019) assessed the clinical 
significance of serum adiponectin in 53 endometrial cancer patients with an 
average age of 54.93 ± 9.59 years and mean BMI of 25.68 ± 4.08 kg/m2. Their 
mean adiponectin level was 2.09 ± 1.24 µg/ml, which was similar to our 
findings suggesting adiponectin levels may be affected by other factors, apart 
from the process of aging in women with endometrial cancer. Leptin levels 
followed similar levels of expression in the current study compared to the ones 
in the study from the Bermano group (unpublished work); in the healthy 
volunteers, leptin levels were highest in the obese category (78.81 ± 45.4 
ng/ml) compared to the OW (21.95 ± 25.94 ng/ml) and NW (6.38 ± 4.08 
ng/ml) categories. It is noted that the obese healthy volunteers have higher 
leptin levels than the obese endometrial cancer cases (78.81 ng/ml vs 59.4 




obese healthy volunteers and the obese endometrial cancer group (average 
age 30 vs 69 years). Isidori and colleagues (2000) reported decreasing leptin 
levels with increasing age in women, with a consistent fall after the menopause 
(-21% p<0.001). Leptin concentrations fluctuate with the levels of oestrogen 
and progestogen, particularly in pre-menopausal women. Adiponectin, on the 
other hand, do not fluctuate in relation to the sex hormone levels during the 
menstrual cycle (Asimakopoulos et al., 2009).  
TNFα concentration levels in the Bermano group study (unpublished work) 
were raised in the obese compared to the OW and NW (90.81 ± 93.57 pg/ml 
for the obese group; 63.29 ± 109.29 pg/ml for the OW and 19.28 ± 24.10 
pg/ml for the NW group). In the current study, TNFα levels were higher in the 
obese cases and in the NW participant (704 ± 459.7 pg/ml for the obese group 
and 216 pg/ml for the NW participant) compared to the results of the healthy 
volunteers. There was only one value for TNFα levels in the NW group. TNFα is 
raised generally in the obese state, however, the findings in the endometrial 
cancer cases, may suggest that, the higher levels promote the development of 
endometrial cancer. In contrast to our study findings, there was no difference 
in IL-6 concentration levels in the different weight categories in the healthy 
volunteers (obese group 74.03 ± 98.12 pg/ml, the OW 68.12 ± 92.39 pg/ml 
and the NW group, 85.54 ± 104.90 pg/ml) of the Bermano group study. In the 
current study IL-6 levels were 182.45 ± 188.89 pg/ml in the obese group, 2.42 
pg/ml in the OW group and 0.6 pg/ml in the NW group. The IL-6 levels in the 
obese case was higher than in the obese healthy volunteer but did not reach 
statistical significance (p=0.25) but lower in the OW and NW cases compared 
to the OW and NW healthy volunteers. It is not immediately apparent why 
there are inconsistencies between IL-6 concentration levels in the study from 
the Bermano group and the current study. Park et al. (2004) assessed IL-6 
levels in 46 obese subject and 54 non obese subject (both groups with a mean 
age of 36 years) and demonstrated that the median concentration of IL-6 were 
significantly higher (p<0.05) in the obese group compared to the non-obese 
group. IL-6 was measured using the ELISA method in the current study and by 
Park et al. (2005). It was not used to measure IL-6 levels in the Bermano 




In conclusion, except for adiponectin, higher concentrations of leptin, TNFα, IL-
6, IGF-I and IGF-II were observed in the obese patients with endometrial 
cancer compared to OW and NW patients. Our study is the first to assess 6 
adipocytokines in a single sample of women of different weight categories, 
diagnosed with endometrial cancer. These preliminary results suggest 
differences in adipocytokines serum concentration levels between obese, 
overweight and normal weight women, which may play a role in the 
development of endometrial cancer, although further larger studies are 




CHAPTER 4: DISCUSSION AND CONCLUSION 
 
Altered cell metabolism and dysfunctional signalling pathways are a common 
occurrence in obesity and is an accepted hallmark of cancer (Hanahan and 
Weinberg, 2011). Adipocytokines are mediators in the initiation of neoplastic 
development and progression and may exert their cancer risk as a result of 
different biological effects. These include (1) altered plasma or serum 
concentrations of adipocytokines in cancer patients; (2) their contrasting 
expression of adipocytokines in cancerous and non-cancerous lesions; (3) their 
up-regulation of adipocytokines in malignant tissues; (4) the association of 
genetic polymorphism of adipocytokines genes with increased risk to certain 
cancers (Spyrou et al., 2018). The exact role of adipocytokines associated 
intracellular signalling pathways within adipose tissue, and the development of 
endometrial cancer, remains to be still unclear.  
This project aimed to partially address this lack of understanding by carrying 
out a systematic review/ meta-analysis of primary studies related to the role 
of adipokines and inflammatory molecules in the development of endometrial 
cancer. By undertaking such a review/ meta-analysis it was hoped that  further 
clarification into the relationship between  endometrial cancer and circulating 
levels of adiponectin and leptin, and also the assessment into the relationship 
between exposure to cytokines (IL-6 and TNFα) and growth factors (IGF-I and 
IGF-II) with endometrial cancer risk could be determined.  
A small clinical study was also undertaken to examine blood concentration 
levels of adiponectin, leptin, TNFα, IL-6, IGF-I and IGF-II in women with 
endometrial cancer and to assess whether CRP and WCC were elevated in 
women with endometrial cancer. It was also important to investigate whether 
there was a correlation between levels of the serum adipocytokines and BMI. 
 
 
Association of circulating levels of adiponectin and leptin with 
endometrial cancer risk 
A meta-analysis of fourteen studies evaluated adiponectin levels and its 




endometrial cancer cases and 3,593 controls were assessed in 14 studies. Our 
combined data noted a significant inverse relationship between adiponectin 
levels and endometrial cancer risk; SOR 0.51, 95% CI: 0.38-0.069, 
p<0.00001. The results suggest highest adiponectin levels compared to the 
lowest levels were significantly associated with reduced risk of endometrial 
cancer. Participants with adiponectin concentrations in the highest tertile had 
a 51% decreased risk of endometrial cancer compared to those women with 
adiponectin concentration levels in the lowest tertile. There was significant 
heterogeneity, I2=77% p<0.00001.  
Stratified and sub analyses were performed, and these did not alter the findings 
of increased adiponectin levels and a reduced risk of endometrial cancer. 
Seven studies; four retrospective and three prospective, assessed the 
association between circulating leptin concentrations and the risk of 
endometrial cancer. One thousand, one hundred and ninety-nine endometrial 
cancers cases and 2076 controls were assessed in the seven studies. Our meta-
analysis demonstrated increased levels of leptin was associated with 
endometrial cancer risk; SOR 2.19, 95% CI: 1.45-3.30, p=0.01. Women with 
leptin concentrations in the highest tertile had a 219% times increased risk of 
endometrial cancer compared to the women with leptin concentrations in the 
lowest tertile. There was variation between the studies, which was considered 
heterogenous, I2=64%, p=0.002. Stratified and sub analyses were also 
performed, and these results did not alter the findings that higher leptin levels 
were associated with a risk of endometrial cancer.  
The meta-analysis results correlated with the clinical study with regards to 
adiponectin levels but not for leptin. In the clinical study, only 2 healthy control 
values were available for adiponectin and leptin measurement (mean control 
value for adiponectin 2.45 µg/ml and for leptin 21.3 ng/ml). However, when 
evaluating the individual studies in the meta-analysis, the control group 
generally had higher adiponectin levels than the endometrial cancer cases. 
Lower levels of adiponectin levels were found in the endometrial cancer cases 
compared to the healthy controls and therefore reinforced the association 
between low adiponectin levels and endometrial cancer. Moreover, when 




different BMI in the clinical study, there was no difference in adiponectin levels 
across the different weight categories, making it difficult to distinguish if it is 
the low adiponectin levels associated to cancer status which play a more 
important role in the initiation of endometrial cancer or the increase in BMI. 
Low circulating adiponectin levels result in reduced anti-proliferative effects 
thereby increasing tumour proliferation and decreased cell apoptosis. Higher 
leptin levels were noted in the obese endometrial cancer cases (59.41 ng/ml) 
compared to the healthy controls (mean value 21.3 ng/ml) but not in the OW 
and NW groups (16.23 ng/ml and 14.23 ng/ml, respectively) Higher leptin 
levels in the obese endometrial cancer cases suggest leptin may also be 
involved in the initiation and development of endometrial cancer.  
 
Association of circulating levels of TNFα, IL-6, IGF-I and IGF-II with 
endometrial cancer risk. 
There have been very few studies analysing the circulating levels of TNFα, IL-
6, IGF-I and IGF-II and their association with the risk of endometrial cancer. 
Two studies assessed both TNFα and IL-6 in a single cohort and a further 2 
studies assessed TNF-α and IL-6 only. There was only one study investigating 
the role of IGF-I and the risk of endometrial cancer. The total number of 
endometrial cancer and control cases for TNF-α was 940 and 1781 respectively 
and for IL-6, 975 and 1837, respectively. The prospective study assessing IGF-
I and its correlation with endometrial cancer risk had 166 cases and 315 
controls. The pooled results from the meta-analyses on TNFα and IL-6 studies 
demonstrated no significant association to  endometrial cancer risk in patients 
with high levels of TNFα and IL-6 when compared to low levels; SOR 1.30 95% 
CI: 0.87-1.95, p=0.06 for TNFα and SOR 1.21 95% CI: 0.85-1.72, p=0.14 for 
IL-6. 
In our clinical study, TNFα concentration levels were lower in the obese 
endometrial cancer cases compared to the single healthy control value that 
was available (704 pg/ml vs 826 pg/ml) and IL-6 concentration levels higher 
in the endometrial cancer cases compared to the healthy controls (182.45 
pg/ml vs 75.91 pg/ml). However, when assessing TNFα and IL-6 circulating 
levels in the different weight categories, TNFα and IL-6 were both raised in the 




cases. Leptin can stimulate the production of TNFα and IL-6; higher leptin 
levels were found in the obese endometrial cancer cases compared to the OW 
and NW group. These results suggest that leptin may act synergistically with 
TNFα and IL-6 to increase the risk and development of endometrial cancer in 
women of different weight categories. Hyperleptinaemia, as a result of obesity, 
promotes low grade inflammation by increasing TNFα and IL-6 levels. The 
higher the BMI, the more TNFα and IL-6 is present to initiate the changes 
necessary for the development of endometrial cancer. 
  
Assessment of blood concentration levels of adiponectin, leptin, TNFα, 
IL-6, IGF-I, IGF-II in women with endometrial cancer  
Twenty-four patients with a diagnosis of endometrial cancer, one with 
endometrial hyperplasia and 2 patients without endometrial cancer were 
included in this study. There was no significant difference in the adiponectin 
serum concentration between the obese, OW and NW cancer patients.  
Leptin concentration was significantly higher (p=0.0065) in the obese group 
compared to the NW group but not when statistically different comparing the 
OW group to the NW group (p=0.55).  
TNFα levels were significantly higher in the obese category compared to OW 
group (p=0.01). IL-6 levels in the obese group were also higher (182.45 ± 
188.99 pg/ml) than compared to the other groups; however, only one value 
was available in the OW and normal group respectively. Leptin may act 
synergistically with TNFα and IL-6 to increase the risk and development of 
endometrial cancer in women of different weight categories.  
IGF-I concentration levels in the obese and OW categories demonstrated a 
dramatic increase when compared to the NW group. There was a statistical 
difference (p=0.04) between the IGF-I levels in the obese category compared 
to the OW category. The IGF-II levels between the obese group and the OW 
group was also statistically significant (p=0.049). Low adiponectin levels in the 
obese endometrial cancer case result in a decrease in IGFBPs. This may result 
in an increase in circulating IGF-I and IGF-II levels in the endometrial cancer 
cases. These results suggest that adipocytokines may act synergistically in the 





Are CRP and WCC elevated in women with endometrial cancer and is 
there a correlation between levels of serum adipocytokines and BMI? 
Only 2 out of the 16 obese patients had a raised CRP of 14 mg/L and 32 mg/L 
respectively (normal range 10 mg/L) and one of the 5 normal weight patients 
had a raised CRP of 20 mg/mL. These results suggest that CRP and WCC count 
are not routinely elevated in women with endometrial cancer. We assessed 
whether there was a correlation between levels of serum adipocytokines and 
BMI and apart from adiponectin, leptin, TNFα, IL-6, IGF-I and IGF-II were all 
raised in the obese group compared to the other weight categories (NW and 
OW). IL-6 stimulates the release of CRP and also the enzyme, aromatase, in 
the adipose tissue, which increases the production of oestrogen through its 
conversion of androstenedione to oestrone. It is apparent from the results that 
IL-6 in the endometrial cancer cases may not stimulate the release of CRP. 
However, IL-6 may be responsible for elevating the circulating oestrogen levels 
and therefore be involved in the development of endometrial cancer. 
This study is the first to assess the serum concentration levels of 6 
adipocytokines simultaneously and their relationship with obesity and 
endometrial cancer in a single project. The interaction of these adipocytokines 
(present in the serum most probably secreted by adipose tissue) with other 
molecular signalling pathways may contribute to the development of 
endometrial cancer. Large prospective studies will need to be undertaken to 
identify the molecular mechanisms involved and the individual roles of each of 
these adipocytokines.  
There were limitations to the study due to time constraints: there were fewer 
cases and age match controls in the clinical study and therefore the sample 
size was very small. The inherent disadvantage of bias in retrospective case 
control studies was also a factor that limited the study. There were also 
limitations when performing the systematic review and meta-analysis. Only 
manuscripts published in English were included in our meta-analysis. No 
unpublished studies were included in our meta-analysis and therefore this 
could possibly misrepresent the results. There were bias risks in the primary 
studies such as heterogeneity in the methodology and variations in the 








Future work should focus on assessing the relationship between adipocytokines 
in the serum, visceral and subcutaneous adipose tissue and endometrial cancer 
and its association to different weight categories. The meta-analysis has 
provided a good foundation for the design of larger prospective studies which 
will assess a variety of adipocytokines in the same cohort of patients in order 
to investigate further the association between adipocytokines and endometrial 
cancer; especially studies considering circulating levels of TNFα, IL-6 and IGF-
I and II, would allow elucidating, in more details, the exact mechanisms 
underlying the link between adipocytokines and endometrial cancer. A 
prospective study which measures serum adiponectin, leptin, TNFα, IL-6 IGF-
I and IGF II concentration levels in obese and normal weight healthy 
volunteers, and assesses their risk for endometrial cancer over time, could be 
carried out in the future. Meanwhile blood samples from patients with EC and 
different BMI could be collected in addition to blood from healthy, obese and 
normal weight volunteers in order to be able to dissect the relationship between 
obesity and EC aetiology/progression. Finally, the correlation between the 
presence of adipocytokines in endometrial tumour cells, serum and the cancer 
stage should be investigated, by collecting tissue biopsies from the cancer 
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